Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experience NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced ...

MagnetisMM-32 is an open-label, multicenter, randomized Phase 3 study to evaluate the efficacy and safety of ELREXFIO ...

About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA ...

TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance option NEW ...

LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...

Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig ...

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants Shipping will begin immediately to ensure rapid access to ...

Two pivotal studies of LITFULO™ (ritlecitinib) in nonsegmental vitiligo met their co-primary endpoints, showing significant improvement in facial and total repigmentation versus placebo at Week 52 ...

First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care Broadened approval supported by Phase 3 EV-304 data ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a ...

Approval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors HYMPAVZI is ...

Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 ...